We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HTBK
2301
DELISTED
Heritage Commerce
HTBK
| $443K | ﹤0.01% |
31,405
+1,225
| +4% | +$17.2K |
|
|
SGMO
2302
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $442K | ﹤0.01% |
85,082
+2,549
| +3% | +$10.2K |
|
2303
Malibu Boats
MBUU
$541M
| $440K | ﹤0.01% |
19,607
+860
| +5% | +$17.4K |
|
2304
Mesa Laboratories
MLAB
$557M
| $438K | ﹤0.01% |
3,571
+41
| +1% | +$5.02K |
|
2305
NovoCure
NVCR
$1.73B
| $438K | ﹤0.01% |
54,038
+1,999
| +4% | +$14.4K |
|
|
HDP
2306
DELISTED
Hortonworks, Inc.
HDP
| $438K | ﹤0.01% |
44,694
+2,739
| +7% | +$26.5K |
|
2307
Iovance Biotherapeutics
IOVA
$1.82B
| $437K | ﹤0.01% |
58,670
+2,421
| +4% | +$17.7K |
|
2308
Rigel Pharmaceuticals
RIGL
$681M
| $437K | ﹤0.01% |
13,190
+2,252
| +21% | +$57.4K |
|
|
GCAP
2309
DELISTED
Gain Capital Holdings, Inc.
GCAP
| $437K | ﹤0.01% |
52,485
+2,868
| +6% | +$22.3K |
|
2310
Lands' End
LE
$370M
| $436K | ﹤0.01% |
20,322
+696
| +4% | +$12.3K |
|
2311
A10 Networks
ATEN
$2.13B
| $435K | ﹤0.01% |
47,528
+2,038
| +4% | +$18K |
|
2312
Live Oak Bancshares
LOB
$1.98B
| $434K | ﹤0.01% |
20,049
+996
| +5% | +$21.1K |
|
2313
NACCO Industries
NC
$357M
| $433K | ﹤0.01% |
27,172
+954
| +4% | +$15.9K |
|
|
PRTY
2314
DELISTED
Party City Holdco Inc.
PRTY
| $433K | ﹤0.01% |
30,851
+2,186
| +8% | +$31.4K |
|
|
MACK
2315
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $433K | ﹤0.01% |
17,868
+597
| +3% | +$14.9K |
|
2316
Houlihan Lokey
HLI
$8.77B
| $432K | ﹤0.01% |
12,528
+387
| +3% | +$12.3K |
|
|
LBY
2317
DELISTED
Libbey, Inc.
LBY
| $432K | ﹤0.01% |
29,608
-245
| -0.8% | -$3.99K |
|
|
IXYS
2318
DELISTED
IXYS Corp
IXYS
| $429K | ﹤0.01% |
29,478
-336
| -1% | -$4.29K |
|
2319
Accuray
ARAY
$32M
| $428K | ﹤0.01% |
90,034
+3,166
| +4% | +$16.5K |
|
|
ACRE
2320
Ares Commercial Real Estate
ACRE
$236M
| $427K | ﹤0.01% |
31,878
+836
| +3% | +$11.3K |
|
2321
VSE Corp
VSEC
$5.45B
| $426K | ﹤0.01% |
10,442
+402
| +4% | +$15.6K |
|
|
YELL
2322
DELISTED
Yellow Corporation Common Stock
YELL
| $425K | ﹤0.01% |
38,606
+1,094
| +3% | +$14.2K |
|
2323
Natural Gas Services Group
NGS
$472M
| $424K | ﹤0.01% |
16,293
+522
| +3% | +$14.6K |
|
|
KDNY
2324
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $424K | ﹤0.01% |
7,896
+210
| +3% | +$11.9K |
|
|
AMNB
2325
DELISTED
American National Bankshares Inc
AMNB
| $424K | ﹤0.01% |
11,375
+382
| +3% | +$13.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.